Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
117.70
+0.24 (0.20%)
At close: Jul 25, 2025, 4:00 PM
117.14
-0.56 (-0.48%)
After-hours: Jul 25, 2025, 7:57 PM EDT
Novartis AG Revenue
Novartis AG had revenue of $14.84B in the quarter ending June 30, 2025, with 15.26% growth. This brings the company's revenue in the last twelve months to $55.19B, up 12.95% year-over-year. In the year 2024, Novartis AG had annual revenue of $51.72B with 10.85% growth.
Revenue (ttm)
$55.19B
Revenue Growth
+12.95%
P/S Ratio
4.09
Revenue / Employee
$727,251
Employees
75,883
Market Cap
225.74B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
| Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
| Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
| Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
| Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
| Thermo Fisher Scientific | 43.21B |
NVS News
- 11 hours ago - 3 Pharma Stocks That Aren't Sweating the Coming 200% Drug Tariffs - Benzinga
- 1 day ago - Novartis to pay Matchpoint up to $1 billion to develop anti-inflammatory therapies - Reuters
- 1 day ago - Matchpoint Therapeutics Announces Exclusive Option and License Agreement with Novartis to Develop Oral Inhibitors for Multiple Inflammatory Diseases - GlobeNewsWire
- 4 days ago - Novartis AG (NVS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Novartis: Q2 Earnings Review - Solid Results Justify All-Time High Share Price - Seeking Alpha
- 8 days ago - Swiss pharma giant Novartis bets on a breast cancer blockbuster as sales rise - CNBC
- 8 days ago - Novartis lifts full-year profit forecast, announces $10 billion share buyback - Invezz
- 9 days ago - Novartis slightly raises 2025 earnings forecast, citing strong Q2 - Reuters